Meeting
2022 ASCO Annual Meeting
Association of interleukin-enhanced factor 2 (ILF2) expression with prognosis and clinico-genomic features in breast cancer (BC).
Authors
Matias A. Bustos
Saint John’s Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA
Matias A. Bustos , Jun Yin , Pavel Brodskiy , Irene Kang , Stephanie L. Graff , Sarah Sammons , Richa Dawar , David Spetzler , Dave S. B. Hoon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1030)
DOI
10.1200/JCO.2022.40.16_suppl.1030
Abstract #
1030
Poster Bd #
408
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
HER2-low breast cancer brain metastases: Incidence and treatment implications.
First Author: Rania Chehade
Poster
2023 ASCO Genitourinary Cancers Symposium
An assessment of the penile squamous cell carcinoma surfaceome for therapeutic target discovery.
First Author: George Daniel Grass
Poster
2022 ASCO Annual Meeting
CK+/CD45+ (dual-positive) circulating cells are associated with prognosis in patients with advanced breast cancer.
First Author: Carolina Reduzzi
Poster
2022 ASCO Genitourinary Cancers Symposium
Prognostic value of HER2 expression levels for upper tract urothelial carcinoma.
First Author: Siming Li